Added to YB: 2025-09-30
Pitch date: 2025-09-26
EXOZ [neutral]
eXoZymes, Inc.
-8.66%
current return
Author Info
Slack Capital is an investment publication dedicated to sharing only a select few opportunities each year. Through 12 years of investing, I have found that deep research and a focused concentration have consistently outperformed a broad, generalised approach. By making informed, strategic investments, I have been able to generate significant returns while consistently strengthening my confidence in my allocation decisions. At the core of Slack Capital's publication are the offered investment reports, often the result of over 50 hours of research, where all available information on a company is meticulously compiled and filtered into a centralised analysis. Sign up for the newsletter.
Company Info
eXoZymes, Inc. operates as a development stage biotechnology company. The company focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing.
Market Cap
$137.6M
Pitch Price
$15.70
Price Target
N/A
Dividend
N/A
EV/EBITDA
-16.02
P/E
-15.94
EV/Sales
N/A
Sector
Biotechnology
Category
growth
eXoZymes - Snapshot Investment Case
EXOZ (update): Cell-free biomanufacturing platform w/ 96% yields, 99% purity vs traditional cell-based methods. 80% enzyme stability gains in 3 weeks vs 20% in 4 months traditionally. NCT compound (fatty liver disease treatment, $17.6B market) produced 4g in single cycle vs requiring 1,600 plants extraction. 130+ active engagements, 3 deals finalizing. Targeting nutraceuticals ($105B TAM) & pharma ($255B TAM). Current $120M market cap.
Read full article (6 min)